United Therapeutics (UTHR) Tops Q3 EPS by 120c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cowen Remains Bullish on United Therapeutics (UTHR) as Orenitram Continues to Grow
October 27, 2015 4:01 PM EDTCowen reiterated an Outperform rating and $185.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings results. All pulmonary hypertension products beat expectations, driving revenue and EPS above consensus.
Analyst Phil Nadeau commented, "UTHR reported strong Q3 results this morning. All pulmonary... More
Leerink Partners Reiterates Market Perform Following United Therapeutics (UTHR) 3Q beat
October 27, 2015 1:44 PM EDTLeerink Partners reiterated a Market Perform rating and $166.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings report. UTHR reported 3Q revenues and non-GAAP EPS of $386M and $3.55 that beat Street estimates of $362M and $3.22. Management reported that sales... More
